Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abaloparatide Transdermal in Postmenopausal Osteoporosis
NCT01674621Phase 2Completed
- Sponsor
- Radius Health Inc
- Start
- Sep 2012
- Primary completion
- Aug 2013
- Modality
- Peptides
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of abaloparatide in postmenopausal osteoporosis (5 arms), sponsored by Radius Health Inc. Primary endpoint: Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at 6 months. Started Sep 2012; status: completed.
02
Drugs
abaloparatide
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT01674621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01674621.